Posted on 12/9/19
Zentalis Pharmaceuticals Raises $85 Million in Oversubscribed Series C
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics
Posted on 12/9/19
Bristol-Myers Squibb Prescribed For The Newborn Portfolio
SummaryNewborn Portfolio update; increase in cash position, as well as a new position added in the portfolio.After a lot of homework and research, Bristol-Myers Squibb was . . .
Posted on 12/9/19
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
With the market at an all-time high, an investor would be hard-pressed to find a stock trading at an earnings multiple that's less than its growth . . .
Posted on 12/9/19
Better Buy: Pfizer vs. Bristol-Myers Squibb
A lot is changing for two of the biggest drugmakers on the planet. Pfizer (NYSE:PFE) is merging its Upjohn business with Mylan (NASDAQ:MYL). Bristol-Myers Squibb (NYSE:BMY) . . .
Posted on 12/9/19
Why Biogen’s Alzheimer’s Drug Presentation Left Investors Uninspired
Investors eagerly awaited Biogen's (NASDAQ:BIIB) presentation on its investigative Alzheimer's drug at Thursday's Clinical Trials on Alzheimer's Disease conference. They were hoping for clues about whether . . .
Posted on 12/9/19
Better Buy: Biogen vs. Amgen
If you only picked which stocks to buy based on performance in recent years, Amgen (NASDAQ:AMGN) would be the hands-down winner over Biogen (NASDAQ:BIIB). Amgen has . . .
Posted on 12/5/19
Harvard Pilgrim Health Care And Ride Health Collaborate
Harvard Pilgrim Health Care and Ride Health have announced a collaboration to offer non-emergency medical transportation at no cost for Medicare Advantage members in Massachusetts and . . .
Posted on 12/5/19
Abacus Health Products Announces Voluntary Extension of Lock-Up Agreements
WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) today announced that it has secured from key shareholders a voluntary extension to lock-up . . .
Posted on 12/5/19
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced that it . . .
Posted on 12/5/19
Here's Why Vertex Pharmaceuticals Rose 13.4% in November
What happenedShares of Vertex Pharmaceuticals (NASDAQ:VRTX) gained more than 13% last month, according to data from S&P Global Market Intelligence. The monthly surge continued a sudden . . .
Posted on 12/5/19
Why CVS Health Stock Gained 13% Last Month
What happenedShares of CVS Health (NYSE:CVS) were climbing last month after the healthcare specialist posted strong third-quarter numbers and an activist investor revealed a stake in . . .
Posted on 12/5/19
Why IDEXX Laboratories Stock Dropped 12% in November
What happenedShares of IDEXX Laboratories (NASDAQ:IDXX) fell 11.7% last month, according to data provided by S&P Global Market Intelligence.IDEXX stock rose steadily through the first half . . .
Posted on 12/5/19
Planet Fitness Announces Accelerated Share Repurchase Program
Planet Fitness, Inc. (NYSE: PLNT) announced that it has entered into a $300 million accelerated share repurchase agreement with JPMorgan Chase Bank, National Association. The Company will . . .
Posted on 12/4/19
Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts
Thermo Fisher Scientific Inc., the world leader in serving science, officially opened its new $90 million viral vector CDMO (contract development and manufacturing organization) site in . . .
Posted on 12/4/19
LEO Pharma and Portal Instruments Announce Collaboration
BALLERUP, Denmark & CAMBRIDGE, Mass.--(BUSINESS WIRE)--LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery . . .
Posted on 12/4/19
Civetta Therapeutics Announces $53 million Series A
Civetta Therapeutics, LLC announced a $53 million Series A financing to advance select programs and a proprietary platform focused on beta-propeller proteins.
Posted on 12/4/19
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement
MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics discovery platform to achieve higher probabilities of . . .
Posted on 12/4/19
Planet Fitness Completes Securitized Financing Transaction
Planet Fitness, Inc. (NYSE: PLNT) today announced that it has completed its previously announced issuance of $550 million of Series 2019-1 Class A-2 Fixed Rate Senior . . .
Posted on 12/3/19
TriNetX Expands into South Korea in Partnership with EvidNet
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), has expanded into South Korea in . . .
Posted on 12/3/19
Merrimack Receives $5 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the . . .
Posted on 12/3/19
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
BOSTON--(BUSINESS WIRE)--Kyn Therapeutics, a clinical-stage biotechnology company, today announced it is rebranding to Ikena Oncology. The rebranding reflects the evolution of the Company beyond its continued . . .
Posted on 12/3/19
EyePoint Pharmaceuticals Faces A Big Opportunity
SummaryThe company has launched two products, DEXYCU and YUTIQ. Both have very substantial market potential, and orders are ramping fast.Due to a situation with its distributor, . . .
Posted on 12/3/19
3 Biotech Stocks With a Lot to Prove at ASH 2019
It's nearly time for the annual get-together of the American Society of Hematology (ASH). There will be presentations from too many drugmakers for any one person . . .
Posted on 12/3/19
Royal Philips Joins AMSUS Executive Advisory Board
ANDOVER, Mass.--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and AMSUS, The Society of Federal Health Professionals, have announced that Philips . . .
Posted on 12/2/19
Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia
CTP-692 Offers Potentially New Approach as an Adjunctive Treatment to Improve Overall Symptoms in Patients with SchizophreniaLEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced . . .

